[go: up one dir, main page]

BR9408378A - Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos - Google Patents

Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos

Info

Publication number
BR9408378A
BR9408378A BR9408378A BR9408378A BR9408378A BR 9408378 A BR9408378 A BR 9408378A BR 9408378 A BR9408378 A BR 9408378A BR 9408378 A BR9408378 A BR 9408378A BR 9408378 A BR9408378 A BR 9408378A
Authority
BR
Brazil
Prior art keywords
patient
nervous system
central nervous
stroke
pharmaceutically acceptable
Prior art date
Application number
BR9408378A
Other languages
English (en)
Inventor
John M Carney
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Publication of BR9408378A publication Critical patent/BR9408378A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9408378A 1993-12-23 1994-12-22 Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos BR9408378A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,579 US5488145A (en) 1993-12-23 1993-12-23 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
PCT/US1994/014545 WO1995017876A2 (en) 1993-12-23 1994-12-22 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps

Publications (1)

Publication Number Publication Date
BR9408378A true BR9408378A (pt) 1997-08-19

Family

ID=22632663

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9408378A BR9408378A (pt) 1993-12-23 1994-12-22 Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
BR1100626-9A BR1100626A (pt) 1993-12-23 1997-05-13 Composto, sal farmaceuticamente aceitável, e, composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR1100626-9A BR1100626A (pt) 1993-12-23 1997-05-13 Composto, sal farmaceuticamente aceitável, e, composição farmacêutica

Country Status (28)

Country Link
US (4) US5488145A (pt)
EP (1) EP0736004B1 (pt)
JP (3) JP3412821B2 (pt)
KR (1) KR100370522B1 (pt)
CN (1) CN1070176C (pt)
AT (1) ATE192736T1 (pt)
AU (1) AU679835B2 (pt)
BR (2) BR9408378A (pt)
CA (1) CA2179521C (pt)
CZ (1) CZ289629B6 (pt)
DE (1) DE69424441T2 (pt)
DK (1) DK0736004T3 (pt)
ES (1) ES2145264T3 (pt)
FI (1) FI111718B (pt)
GR (1) GR3034134T3 (pt)
HR (1) HRP950358B1 (pt)
HU (1) HU221167B1 (pt)
MY (1) MY114178A (pt)
NO (1) NO306457B1 (pt)
NZ (1) NZ279025A (pt)
PL (1) PL185189B1 (pt)
PT (1) PT736004E (pt)
RU (1) RU2159231C2 (pt)
SG (1) SG64903A1 (pt)
SK (1) SK282403B6 (pt)
TW (1) TW299315B (pt)
UA (1) UA45964C2 (pt)
WO (1) WO1995017876A2 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
KR960008230B1 (ko) * 1989-10-17 1996-06-21 윌리엄 쥐.씨먼 중추신경계의 산화적 손상에 관련된 질병들을 억제하기 위한 조성물들
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
WO1997010218A1 (en) * 1995-09-11 1997-03-20 Hoechst Marion Roussel, Inc. Cyclic nitrones and pharmaceutical compositions containing them
JP3887020B2 (ja) * 1995-11-17 2007-02-28 フロリダ インターナショナル ユニバーシティー アズレニルニトロンスピントラッピング剤、ならびにその製造方法および使用方法
WO1997038683A1 (en) * 1996-04-17 1997-10-23 Oklahoma Medical Research Foundation Nitrone free radical trap treatment of dementia associated with aids virus (hiv-1) infection
IL128070A0 (en) * 1996-07-19 1999-11-30 Centaur Pharmaceuticals Inc Furan nitrone compounds
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6046232A (en) 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
US5998469A (en) * 1998-01-16 1999-12-07 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
JP2002509147A (ja) * 1998-01-16 2002-03-26 センター ファーマシューティカルズ， インコーポレイテッド チオフェンニトロン化合物
CA2323490A1 (en) * 1998-03-13 1999-09-16 Lowell D. Waterbury Inhibition of angiogenesis
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
EP1077696A1 (en) * 1998-05-19 2001-02-28 Centaur Pharmaceuticals, Inc. Furan nitrone therapeutics for the treatment of inflammatory bowel disease
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) * 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
EP1616869B1 (en) 1999-01-25 2012-04-04 National Jewish Health Substituted porphyrins and their therapeutic use
JP4726304B2 (ja) * 1999-04-28 2011-07-20 ベルス ヘルス （インターナショナル） リミティッド アミロイドーシスを治療するための組成物および方法
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
AU1574701A (en) * 1999-10-22 2001-04-30 Wrair Walter Reed Army Institute Of Research A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
SE0000055D0 (sv) * 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
WO2001051459A1 (en) * 2000-01-10 2001-07-19 Centaur Phamaceuticals, Inc. Method for the purification of aryl sulfonic acids and salts
SE0000056D0 (sv) 2000-01-10 2000-01-10 Astrazeneca Ab Novel process
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
AU2002253857A1 (en) 2001-01-08 2002-09-04 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
WO2003010154A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
BRPI0517790A (pt) * 2004-11-12 2008-10-21 Neurochem Int Ltd métodos e composições fluoradas para tratar doenças relacionadas à amilóide
CA2586334A1 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
CA2592320C (en) * 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007013842A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
WO2007013841A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema
WO2007013844A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea
WO2007013843A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia
WO2007125385A2 (en) * 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
AU2007277193B2 (en) * 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
EP2120905A1 (en) * 2006-12-22 2009-11-25 BELLUS Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
EP2572675B1 (en) 2007-09-26 2016-06-22 St. Jude Medical, Inc. Collapsible prosthetic heart valves
CN104622879A (zh) * 2008-02-12 2015-05-20 托斯克公司 减少毒性的多柔比星助剂及其使用方法
ES2600469T3 (es) * 2008-05-23 2017-02-09 National Jewish Health Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
AU2009288057B2 (en) * 2008-09-02 2014-07-03 Oklahoma Medical Research Foundation 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
WO2011028503A1 (en) * 2009-08-24 2011-03-10 Hough Ear Institute Methods for treating acute acoustic trauma
EP2670403B1 (en) 2011-02-04 2021-08-18 Hough Ear Institute Methods for treating brain injury
EP3532042A4 (en) 2016-10-31 2020-06-24 Hough Ear Institute METHOD FOR IMPROVING SYNAPTOGENESIS AND NEURITOGENESIS
CN110392568A (zh) 2017-01-19 2019-10-29 耳科制药公司 N-乙酰半胱氨酸的制剂及其用途
JP7254780B2 (ja) 2017-09-20 2023-04-10 オクラホマ・メディカル・リサーチ・ファウンデーション 薬剤耐性神経膠腫の治療法
US10829441B2 (en) 2017-11-14 2020-11-10 The University Of Toledo Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
EP3787750A1 (en) * 2018-05-03 2021-03-10 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
CA3111793A1 (en) 2018-09-12 2020-03-19 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
WO2021173702A1 (en) * 2020-02-24 2021-09-02 Oblato, Inc. Compositions and methods for treating cancer and tumor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914650A1 (de) * 1989-05-03 1990-11-08 Basf Ag Neue phenylendiamine sowie ein verfahren zur herstellung von phenylendiaminen
KR960008230B1 (ko) * 1989-10-17 1996-06-21 윌리엄 쥐.씨먼 중추신경계의 산화적 손상에 관련된 질병들을 억제하기 위한 조성물들
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
DE3937342A1 (de) * 1989-11-09 1991-05-16 Bayer Ag Verfahren zur herstellung von 2-aminobenzol-disulfonsaeuren-(1,4) und die neue verbindung 6-chlor-2-aminobenzol-disulfonsaeure-(1,4)
CA2111836C (en) * 1991-06-18 2006-08-29 John M. Carney Spin-trapping pharmaceutical compositions and methods for use thereof
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
FI962589L (fi) 1996-08-20
RU2159231C2 (ru) 2000-11-20
DE69424441T2 (de) 2000-10-12
CZ289629B6 (cs) 2002-03-13
GR3034134T3 (en) 2000-11-30
HRP950358A2 (en) 1997-08-31
TW299315B (pt) 1997-03-01
CZ177596A3 (en) 1996-12-11
US5508305A (en) 1996-04-16
HK1008294A1 (en) 1999-05-07
NO962637D0 (no) 1996-06-20
CN1070176C (zh) 2001-08-29
DE69424441D1 (de) 2000-06-15
HK1001768A1 (en) 1998-07-10
HRP950358B1 (en) 2001-04-30
PL185189B1 (pl) 2003-03-31
EP0736004A1 (en) 1996-10-09
NO306457B1 (no) 1999-11-08
ATE192736T1 (de) 2000-05-15
WO1995017876A3 (en) 1995-08-10
UA45964C2 (uk) 2002-05-15
HU9601739D0 (en) 1996-08-28
CA2179521A1 (en) 1995-07-06
ES2145264T3 (es) 2000-07-01
US5488145A (en) 1996-01-30
SG64903A1 (en) 1999-05-25
HUT76788A (en) 1997-11-28
JP2004075696A (ja) 2004-03-11
AU679835B2 (en) 1997-07-10
FI111718B (fi) 2003-09-15
PT736004E (pt) 2000-09-29
PL315154A1 (en) 1996-10-14
JP2001010953A (ja) 2001-01-16
MY114178A (en) 2002-08-30
BR1100626A (pt) 1999-11-23
US5475032A (en) 1995-12-12
CN1156447A (zh) 1997-08-06
JP3412821B2 (ja) 2003-06-03
FI962589A0 (fi) 1996-06-20
HU221167B1 (en) 2002-08-28
NO962637L (no) 1996-08-13
KR100370522B1 (ko) 2003-05-16
JPH09507232A (ja) 1997-07-22
NZ279025A (en) 1998-02-26
EP0736004B1 (en) 2000-05-10
AU1552795A (en) 1995-07-17
SK78896A3 (en) 1997-09-10
US5780510A (en) 1998-07-14
WO1995017876A2 (en) 1995-07-06
CA2179521C (en) 2002-03-19
SK282403B6 (sk) 2002-01-07
DK0736004T3 (da) 2000-10-09

Similar Documents

Publication Publication Date Title
BR9408378A (pt) Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR9908488A (pt) Composição farmacêutica de topiramato
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BRPI0011867B8 (pt) preparação farmacêutica de levodopa/carbidopa/entacapona e processo para preparação da mesma
KR940703676A (ko) 알렌드로네이트를 사용한 치근막 질환의 치료방법(Treatment of periodontal disease with alendronate)
DE69034043D1 (de) Pcp-rezeptor-liganden und deren verwendung
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
KR970025615A (ko) 암 전이 억제제
BR9607964A (pt) Processo de preparação de um medicamento para tratar doença inflamatória do intestino
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
DK0378146T3 (da) Polyamin-derivater som antineoplastiske midler
KR930702985A (ko) 식도암의 치료
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
BR9808305A (pt) Forma hidratada cristalina, processo para a preparação da forma hidratada cristalina, composição farmacêutica, processo de tratamento de um mamìfero, e, processo de tratamento ou de prevenção de dor.

Legal Events

Date Code Title Description
FA Application withdrawn